Tuesday, March 22, 2011

Don't Stop Tamoxifen Early, Study Says

Five years of Tamoxifen reduces cancer: study

 
A study conducted by the researchers based at the Cancer Research UK and UCL Cancer Trials Centre for Tamoxifen, demonstrated that the cancer was less likely to come back in women who took the drug for five years, compared to two years.

The results of the trial, with 3,500 patients, suggested that the cancer came back in around 40% of the patients who took the medicine for five years, as compared to those who has taken Tamoxifen for two years.

According to the scientists, taking Tamoxifen for five years gives the best chance of survival from breast cancer.

Cancer Research UK Clinical Research director Kate Law said this large Cancer Research UK-funded study is the first to look at the long-term performance of Tamoxifen - considered to be one of the most important drugs in the history of breast cancer treatment.

"Our research is behind many important drugs, including Tamoxifen, that have contributed to more than three quarters of women with breast cancer now surviving their disease for ten years or more," Law said.
http://contractresearch.pharmaceutical-business-review.com/news/five-years-of-tamoxifen-reduces-cancer-study-220311

No comments: